Clinical Trial Update: A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating safety and tolerability of olipudase alfa in pediatric and adult participants with acid sphingomyelinase deficiency (ASMD) who comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acid Sphingomyelinase Deficiency

Drugs mentioned

• XENPOZYME (olipudase alfa-RPCP)

Snippet

Sponsor: Sanofi | Conditions: Acid Sphingomyelinase Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2026-04-13